Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

enVVeno Medical (NVNO) Capital Expenditures (2017 - 2024)

enVVeno Medical has reported Capital Expenditures over the past 4 years, most recently at $27540.0 for Q4 2020.

  • For Q4 2020, Capital Expenditures rose 112.55% year-over-year to $27540.0; the TTM value through Dec 2020 reached $180291.0, down 50.45%, while the annual FY2025 figure was $5000.0, 86.49% down from the prior year.
  • Capital Expenditures for Q4 2020 was $27540.0 at enVVeno Medical, up from $24965.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $177230.0 in Q2 2019 and troughed at $1800.0 in Q1 2019.
  • A 4-year average of $55695.8 and a median of $18961.0 in 2019 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 215.79% in 2019 and later plummeted 85.48% in 2020.
  • Year by year, Capital Expenditures stood at $8673.0 in 2017, then tumbled by 52.69% to $4103.0 in 2018, then skyrocketed by 215.79% to $12957.0 in 2019, then skyrocketed by 112.55% to $27540.0 in 2020.
  • Business Quant data shows Capital Expenditures for NVNO at $27540.0 in Q4 2020, $24965.0 in Q3 2020, and $122473.0 in Q2 2020.